Education
About Us
Working with TipRanks
Follow Us
Titan Pharmaceuticals Inc. (TTNP)
:TTNP
RESEARCH TOOLSreports
TTNP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $14.80
Previous CloseN/A
Volume3.24K
Average Volume (3M)67.71K
Market Cap
$4.29M
Enterprise Value$7.73M
Total Cash (Recent Filing)$1.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.23
Shares Outstanding914,234
10 Day Avg. Volume83,665
30 Day Avg. Volume67,706
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-1.28
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue46.56
Enterprise Value/Gross Profit-2.58K
Enterprise Value/Ebitda-0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Titan Pharmaceuticals News
PremiumCompany Announcements
Titan Pharmaceuticals Appoints Chay Weei Jye as CEO
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
1.15% Mutual Funds
<0.01% Other Institutional Investors
98.40% Public Companies and
Individual Investors
TTNP FAQ
What was Titan Pharmaceuticals Inc.’s price range in the past 12 months?
Titan Pharmaceuticals Inc. lowest stock price was $3.03 and its highest was $14.80 in the past 12 months.
What is Titan Pharmaceuticals Inc.’s market cap?
Titan Pharmaceuticals Inc.’s market cap is $4.29M.
When is Titan Pharmaceuticals Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Titan Pharmaceuticals Inc.’s earnings last quarter?
Titan Pharmaceuticals Inc. released its earnings results on Nov 13, 2023. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.022.
Is Titan Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Titan Pharmaceuticals Inc.’s price is currently Overvalued.
Does Titan Pharmaceuticals Inc. pay dividends?
Titan Pharmaceuticals Inc. does not currently pay dividends.
What is Titan Pharmaceuticals Inc.’s EPS estimate?
Titan Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Titan Pharmaceuticals Inc. have?
Titan Pharmaceuticals Inc. has 914,234 shares outstanding.
What happened to Titan Pharmaceuticals Inc.’s price movement after its last earnings report?
Titan Pharmaceuticals Inc. reported an EPS of -$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.556%.
Which hedge fund is a major shareholder of Titan Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in TTNP
Company Description
Titan Pharmaceuticals Inc.
Titan Pharmaceuticals, Inc. (TTNP) is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious medical conditions. With a strong emphasis on the central nervous system and opioid addiction treatment markets, Titan's core product is Probuphine, a unique subdermal implant designed to deliver a continuous and controlled dose of buprenorphine for opioid dependence management.